Value of <sup>68</sup>Ga-DOTATOC and Carbidopa-Assisted <sup>18</sup>F-DOPA PET/CT for Insulinoma Localization.
Where this comes from
- Record sourced from PubMed, PMID 34272321.
- Also identified by DOI 10.2967/jnumed.121.262401 and PMC identifier 8978186.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Our objective was to assess the value of <sup>68</sup>Ga-DOTATOC and carbidopa-assisted <sup>18</sup>F-fluorodihydroxyphenylalanine (<sup>18</sup>F-DOPA) in 21 hypoglycemic patients. <b>Methods:</b> All patients who underwent <sup>68</sup>Ga-DOTATOC or carbidopa-assisted <sup>18</sup>F-DOPA PET/CT for suspicion of insulinoma from January 2019 to January 2021 were retrospectively analyzed. A final diagnosis of insulinoma was determined by pathologic reports or consensus. <b>Results:</b> During the study period, 21 patients underwent both <sup>68</sup>Ga-DOTATOC and <sup>18</sup>F-DOPA PET/CT. A final diagnosis of insulin-secreting tumor was reached in 12 cases, including 11 insulinomas and 1 small mixed neuroendocrine/nonneuroendocrine neoplasm. <sup>18</sup>F-DOPA and <sup>68</sup>Ga-DOTATOC PET/CT were positive in 5 (45%) and 7 (64%) of 11 cases, respectively, with 4 concordant positive findings. Moreover, 1 insulinoma was visualized exclusively by <sup>18</sup>F-DOPA PET/CT and 3 by <sup>68</sup>Ga-DOTATOC PET/CT only. <sup>18</sup>F-DOPA and <sup>68</sup>Ga-DOTATOC PET/CT were falsely positive in 1 nonfunctioning pancreatic neuroendocrine tumor. <b>Conclusion:</b> When <sup>68</sup>Ga-exendin-4 is not available, <sup>68</sup>Ga-somatostatin receptor PET/CT should be the first choice for insulinoma functional imaging.
Medical subject headings
- Insulinoma
- Neuroendocrine Tumors
- Organometallic Compounds
- Pancreatic Neoplasms